EQUITY RESEARCH MEMO
I Peace
Generated 5/10/2026
Executive Summary
Conviction (model self-assessment)65/100
I Peace is a Palo Alto-based contract development and manufacturing organization (CDMO) founded in 2015, specializing in induced pluripotent stem cell (iPSC) technology. The company provides cGMP manufacturing services for iPSC-derived cell products to institutional clients and offers personal iPSC banking for individuals. Its mission is to democratize access to high-quality iPSC manufacturing, thereby accelerating drug discovery and enabling personalized regenerative medicine. By focusing exclusively on iPSC technology, I Peace positions itself as a niche enabler in the rapidly growing cell therapy ecosystem.
Upcoming Catalysts (preview)
- Q3 2026Major cGMP manufacturing contract with a top-10 biopharma45% success
- Q4 2026Expansion of cleanroom capacity or new facility announcement60% success
- H2 2026FDA acceptance of an IND for an iPSC-derived therapy utilizing I Peace's services30% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)